Through a new approach dubbed AMBAR, the biotechnology company Grifols has attempted to reduce the amount of harmful, Alzheimer’s disease-causing amyloid beta in the brain by collecting it with a blood protein called albumin and draining it out of the bloodstream. This approach differs from the previous antibody and catabody approaches and offers new hope…

Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union in New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights. Dr. Sudhir Paul from Covalent Bioscience talks about his…

Today, we are going to be taking a look at GAIM and what it might mean for treating amyloid-based diseases, such as Alzheimer’s, Parkinson’s, and amyloidosis. This approach has the potential to treat multiple age-related diseases at once by targeting a common characteristic that they all share. Misfolded proteins cause multiple age-related diseases Proteins are…

In a study at King’s College London, scientists have shown that a vicious circle in which the ill-famed amyloid-beta protein stimulates its own production might be a key factor in the etiology of neurodegeneration in Alzheimer’s disease; furthermore, a drug known as fasudil seems to be effective against amyloid-beta in a mice model of the…

Scientists at the Mayo Clinic have implicated senescent cells in yet another age-related pathology—namely, Alzheimer’s disease. Led by Dr. Darren Baker, the Mayo Clinic team discovered that clearing senescent microglia and astrocytes in murine brains leads to a much better prognosis for neurodegenerative disease [1]. Study abstract Cellular senescence, which is characterized by an irreversible…

According to a study led by scientists at Massachusetts General Hospital, exercise-induced neurogenesis improves cognition in a mouse model of Alzheimer’s disease, yielding more benefits than drug-induced adult neurogenesis. The scientists were able to figure out the difference between the two types of induced neurogenesis and pharmacologically reproduce the same benefits provided by exercise [1]….

For the first time in an animal model, researchers at the Lewis Katz School of Medicine at Temple University showed that the tau pathology that accompanies Alzheimer’s disease can be reversed using the asthma drug zileuton [1]. Abstract Previous studies showed that the leukotrienes pathway is increased in human tauopathy and that its manipulation may…

Vascular risk appears to be a strong predictor of dementia, especially in older individuals with high levels of brain beta-amyloids, and the interaction between these two risk factors might lead to a higher rate of cognitive decline, according to a recent study at the Massachusetts General Hospital. Alzheimer’s disease (AD) is an age-related neurological disorder…

In April, we talked about new Alzheimer’s research showing how the gene variant ApoE4 greatly increases the risk of developing the disease, and we discussed how researchers have converted the defective gene back to its original form to cut the risk of Alzheimer’s.

A new open access paper takes a look at the potential of regenerative medicine for the treatment of Alzheimer’s disease [1]. The review covers approaches such as spurring the production of new neurons and transplanting new neurons while taking a look at the disease-modeling approaches and techniques that science is now using to refine approaches…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD